Apis Capital Advisors LLC Purchases 50,000 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Apis Capital Advisors LLC increased its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 22.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 274,000 shares of the company’s stock after purchasing an additional 50,000 shares during the quarter. Cellebrite DI makes up 2.4% of Apis Capital Advisors LLC’s holdings, making the stock its 16th largest position. Apis Capital Advisors LLC owned about 0.13% of Cellebrite DI worth $3,274,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Magnetar Financial LLC acquired a new stake in Cellebrite DI during the 2nd quarter valued at $143,000. Sei Investments Co. raised its position in shares of Cellebrite DI by 16.9% in the second quarter. Sei Investments Co. now owns 141,644 shares of the company’s stock valued at $1,693,000 after purchasing an additional 20,478 shares during the period. Public Employees Retirement Association of Colorado acquired a new stake in shares of Cellebrite DI during the 2nd quarter worth about $71,000. Hsbc Holdings PLC boosted its holdings in shares of Cellebrite DI by 44.7% during the 2nd quarter. Hsbc Holdings PLC now owns 238,002 shares of the company’s stock worth $2,866,000 after buying an additional 73,533 shares during the period. Finally, Connors Investor Services Inc. acquired a new position in Cellebrite DI in the 2nd quarter valued at about $1,803,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $17.40 on Monday. The business has a fifty day moving average price of $15.15 and a two-hundred day moving average price of $12.68. The stock has a market capitalization of $3.58 billion, a PE ratio of -30.00, a P/E/G ratio of 2.41 and a beta of 1.52. Cellebrite DI Ltd. has a fifty-two week low of $6.36 and a fifty-two week high of $17.82.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, August 15th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.02. The business had revenue of $95.70 million during the quarter, compared to the consensus estimate of $91.94 million. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. Cellebrite DI’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.05 earnings per share. On average, equities analysts expect that Cellebrite DI Ltd. will post 0.31 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on CLBT shares. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Cellebrite DI from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Lake Street Capital boosted their price target on Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Needham & Company LLC lifted their target price on Cellebrite DI from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, Bank of America upped their price target on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI presently has an average rating of “Buy” and a consensus target price of $17.33.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.